CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0220 (clinicaltrials.gov NCT No: NCT01811212)
Title:Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Principal Investigator:Maria E. Cabanillas
Treatment Agent:XL184
Study Status:Open
Study Description:The goal of this clinical research study is to learn if cabozantinib can help
to control DTC. The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase II
Treatment Agents:XL184
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NCI/CTEP
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Maria E. Cabanillas
Dept:Endocrinology
For Clinical Trial Enrollment:713-563-0764
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults